Revisiting metformin as a chemotherapy adjuvant: a systematic review and meta-analysis based on recent randomized-controlled trials.

Authors

Bushra Wadi Bin Saddiq, Ahmed Salah Morad, Tanveer Nidal Khan, Joud Jamal Alshowaikhat, Jorie Nasser Alsharari, Renad Omar Bajri, Meral Jehad AlZayer, Saaid Mounzer Mouazen, Mohammed Abdulhameed Abutaleb, Suhaib Radi, Hassan Alwafi

Published in

Frontiers in oncology. Volume 16. Pages 1888506. Epub Sep 09, 2026.

Abstract

The primary objective is to assess metformin's impact on progression free survival (PFS), overall survival (OS), and overall response rates (ORR). Secondary objectives included chemotherapy-related toxicity, glucose metabolism, and quality of life.
A systematic review and meta-analysis were conducted following PRISMA guidelines and registered prospectively in PROSPERO. A comprehensive literature search was performed in November 2024 across PubMed, Google Scholar, Ovid MEDLINE, and ClinicalTrials.gov. Randomized controlled trials evaluating metformin as an adjunct to chemotherapy were included. The primary outcomes assessed were PFS, OS, and ORR; secondary outcomes included chemotherapy-related side effects, glucose metabolism, and quality of life. Data extraction and quality assessment were performed using standardized tools, and statistical analyses were conducted using RevMan 5.4 Heterogeneity was assessed using the I² statistic, and a random-effects model was applied when necessary.
Nineteen RCTs involving 3,502 participants were included. Subgroup analyses demonstrated a significant OS benefit when metformin (1500 mg/day) was combined with platinum-based chemotherapy (HR = 0.61, 95% CI 0.46-0.81; p = 0.0006). Metformin also significantly improved ORR in patients with breast cancer (OR = 1.86, 95% CI 1.19-2.92; p = 0.007) and in studies using a 500 mg/day dose (OR = 3.39, 95% CI 1.37-8.39; p = 0.008). Overall, metformin significantly improved ORR (OR = 1.59, 95% CI 1.02-2.46; p = 0.04). However, no significant improvements were observed in overall PFS (HR = 1.08, 95% CI 0.96-1.22; p = 0.19) or OS (HR = 1.08, 95% CI 0.90-1.30; p = 0.41). Grade ≥3 adverse events were comparable between groups (OR = 1.10, 95% CI 0.66-1.84; p = 0.72).
Adjunctive metformin did not improve overall or PFS but was associated with a higher ORR, driven by increased complete responses, without increasing high-grade toxicity. A survival benefit was observed in exploratory subgroup analyses at a 1500 mg/day dose in platinum-based chemotherapy, warranting prospective trials to clarify these findings.

PMID:
42840671
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.